← All trials
NCT05941247
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 17, 2023
- Primary completion
- Aug 8, 2023
- Completion date
- Dec 7, 2023
- First posted
- Jul 12, 2023
- Last posted
- Sep 22, 2023
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hemay Pharmaceutical PTY. LTD.Lead sponsor
- Scientia Clinical Research Limited SydneyOverall official - principal investigator
- Hemay Pharmaceutical PTY. LTD.Collaborator
- Scientia Clinical Research Limited SydneyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.